8-K: Iovance Biotherapeutics Reports Strong Amtagvi Sales, Reaffirms Revenue Guidance

Iovance Biotherapeutics announces positive financial results for Q4 and full year 2024, driven by strong demand for Amtagvi, and reaffirms its revenue guidance for 2025.

Summary

• Iovance Biotherapeutics reported total product revenue of $73.7 million for the fourth quarter of 2024, including $48.7 million from Amtagvi sales and $25.0 million from Proleukin sales.
• Full year 2024 total product revenue reached $164.1 million, achieving the upper end of the company's guidance range of $160 million to $165 million.
• The company is reaffirming its total product revenue guidance of $450 million to $475 million for 2025.
• Iovance expects cash burn for full year 2025 to be under $300 million.
• As of February 26, 2025, Iovance had approximately $422 million in cash, cash equivalents, investments, and restricted cash, which is expected to fund operations into the second half of 2026.
• Regulatory approvals for Amtagvi are expected in the UK, EU, and Canada in 2025.
• Enrollment is accelerating across global registrational trials in frontline advanced melanoma and previously treated advanced NSCLC.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, successful product launch, and reaffirmed guidance. While there are losses, they are decreasing, and the company has a solid cash position. The expansion plans and regulatory progress further contribute to a positive sentiment.

Positives

• Strong early adoption of Amtagvi in the U.S. market is driving revenue growth.
• The company is on track to expand its authorized treatment center (ATC) network and increase patient referrals.
• Regulatory submissions for Amtagvi are progressing in multiple international markets.
• Iovance has a strong cash position to fund operations into the second half of 2026.
• Gross margins are expected to increase over time and surpass 70% over the next several years.
• Reimbursement for Amtagvi remains successful, with approximately 75% of patients covered by private payers.
• Iovance owns more than 250 granted or allowed U.S. and international patents and patent rights for Amtagvi and other TIL-related technologies that are expected to provide Amtagvi with exclusivity through at least 2042.

Negatives

• The company reported a net loss of $78.6 million for the fourth quarter of 2024 and $372.2 million for the full year 2024, although these losses are lower than the previous year.
• Cost of sales for the full year 2024 was $124.0 million, primarily related to costs associated with patient drop off and manufacturing success rates, non-cash amortization expense for intangible assets and fair value mark-up of inventory, and royalties payable on product sales.

Risks

• The company's ability to successfully commercialize Amtagvi and Proleukin is subject to market acceptance, pricing, and reimbursement challenges.
• Manufacturing complexities and potential disruptions could impact the supply of Amtagvi.
• Regulatory approvals in international markets are not guaranteed and may be delayed.
• Clinical trial results may not support registrational studies and subsequent approvals by regulatory authorities.
• Unanticipated expenses may decrease estimated cash balances and forecasts and increase estimated capital requirements.

Future Outlook

Iovance reaffirms its total product revenue guidance of $450 million to $475 million for 2025 and expects significant growth in total product revenue for full year 2026, and beyond. The company also anticipates regulatory approvals for Amtagvi in the UK, EU, and Canada in 2025.

Management Comments

• Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, 'In 2024, we successfully drove strong early adoption for our U.S. commercial launch of Amtagvi for patients with previously treated advanced melanoma.'
• Management is confident that Iovance is well positioned to remain the global leader in innovating, developing, and delivering current and future generations of TIL cell therapy for patients with cancer.

Industry Context

Iovance is a key player in the emerging field of TIL therapy, with Amtagvi being the first FDA-approved T cell therapy for a solid tumor indication. The company's focus on expanding its ATC network and securing regulatory approvals in new markets positions it to capitalize on the growing demand for personalized cancer treatments.

Comparison to Industry Standards

• The 34-day manufacturing turnaround time for Amtagvi is competitive with other cell therapies, such as CAR-T therapies from companies like Novartis (Kymriah) and Gilead (Yescarta), which can have similar or longer turnaround times.
• The projected gross margins surpassing 70% are in line with established biotechnology companies with approved products, such as Amgen and Biogen.
• The company's focus on expanding into new markets aligns with the strategies of other biotechnology companies seeking to maximize the commercial potential of their products, such as Roche and Merck.

Management Changes

Stakeholder Impact

• Shareholders: Positive financial results and future outlook are likely to be well-received.
• Patients: Continued development and approval of TIL therapies offer new treatment options.
• Employees: Expansion and growth create opportunities for career advancement.
• Customers (Healthcare Providers): Increased access to Amtagvi through expanded ATC network.
• Suppliers: Increased demand for manufacturing and supply chain services.

Next Steps

• Continue driving broader adoption and utilization of Amtagvi.
• Increase patient referrals to authorized treatment centers (ATCs).
• Add large community practices to the ATC network.
• Expand the U.S. market for Amtagvi.
• Secure regulatory approvals in the UK, EU, and Canada.
• Share additional data from the IOV-LUN-202 registrational Phase 2 trial in post-anti-PD-1 NSCLC in the second half of 2025.
• Submit an IND in 2025 to support clinical development for IOV-5001.

Key Dates